Aptose Biosciences (NASDAQ:APTO) Rating Increased to Hold at StockNews.com

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other research firms have also commented on APTO. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Aptose Biosciences in a research report on Wednesday. Piper Sandler dropped their price objective on Aptose Biosciences from $12.00 to $5.00 and set an “overweight” rating on the stock in a report on Thursday, February 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $19.80.

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $1.66 on Thursday. The stock’s 50 day moving average price is $1.81 and its 200 day moving average price is $2.34. The firm has a market capitalization of $26.10 million, a PE ratio of -0.22 and a beta of 1.30. Aptose Biosciences has a one year low of $1.36 and a one year high of $9.90.

Institutional Investors Weigh In On Aptose Biosciences

A number of institutional investors have recently made changes to their positions in APTO. Sequoia Financial Advisors LLC bought a new stake in shares of Aptose Biosciences in the 1st quarter valued at approximately $27,000. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Aptose Biosciences in the 4th quarter valued at approximately $32,000. Cetera Advisors LLC increased its holdings in shares of Aptose Biosciences by 40.1% in the 4th quarter. Cetera Advisors LLC now owns 86,827 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 24,847 shares during the last quarter. Millennium Management LLC grew its stake in Aptose Biosciences by 75.4% during the 4th quarter. Millennium Management LLC now owns 222,930 shares of the biotechnology company’s stock worth $129,000 after buying an additional 95,796 shares during the last quarter. Finally, Citadel Advisors LLC grew its stake in Aptose Biosciences by 256.6% during the 4th quarter. Citadel Advisors LLC now owns 61,875 shares of the biotechnology company’s stock worth $155,000 after buying an additional 44,522 shares during the last quarter. 26.62% of the stock is currently owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.